Compare RSG & ZTS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | RSG | ZTS |
|---|---|---|
| Founded | 1996 | 1952 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Environmental Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 67.5B | 54.8B |
| IPO Year | 1998 | 2012 |
| Metric | RSG | ZTS |
|---|---|---|
| Price | $219.50 | $128.78 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 19 | 11 |
| Target Price | ★ $248.32 | $156.20 |
| AVG Volume (30 Days) | 1.4M | ★ 4.3M |
| Earning Date | 05-20-2026 | 05-14-2026 |
| Dividend Yield | 1.13% | ★ 1.67% |
| EPS Growth | 5.55 | ★ 10.05 |
| EPS | ★ 6.85 | 6.02 |
| Revenue | ★ $19,027,000,000.00 | $9,467,000,000.00 |
| Revenue This Year | $5.49 | $5.79 |
| Revenue Next Year | $5.13 | $5.16 |
| P/E Ratio | $32.04 | ★ $21.39 |
| Revenue Growth | ★ 3.31 | 2.28 |
| 52 Week Low | $201.42 | $115.25 |
| 52 Week High | $258.75 | $177.00 |
| Indicator | RSG | ZTS |
|---|---|---|
| Relative Strength Index (RSI) | 53.24 | 51.66 |
| Support Level | $209.48 | $124.50 |
| Resistance Level | $224.61 | $129.98 |
| Average True Range (ATR) | 5.01 | 3.87 |
| MACD | -0.15 | 0.11 |
| Stochastic Oscillator | 57.44 | 56.75 |
Republic Services Group is the second-largest waste management company by revenue and provides integrated waste management services to residential, commercial, and industrial customers. With 208 active landfills, 248 transfer stations, and 75 recycling centers, Republic Services has reached $16 billion in annual revenue, focusing on recycling and environmental solutions. The company reports in three segments based on the Western United States (Group 1), Eastern United States (Group 2), and Environmental Solutions across North America (Group 3). Eighty-nine percent of total revenue comes from recycling and waste, with the remaining 11% from Environmental Solutions.
Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns roughly 35% of total revenue from production animals (cattle, pigs, poultry, and so on) and nearly 65% from companion animal (dogs, horses, cats) products. Its USA business is skewed even more heavily toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.